Funding
Superluminal raises $60M Series B for obesity drug
September 7, 2026
Biotech
Funding
Key Facts
Signal Type
Funding
Industry
Biotech
Companies
Superluminal Medicines, BVF Partners, RA Capital Management, Eli Lilly and Company, NVIDIA
Date
September 7, 2026
Superluminal Medicines, a Boston-based biotech, raised $60M in an oversubscribed Series B round led by BVF Partners. New investors Deep Track Capital and Perceptive Advisors joined, with continued support from RA Capital Management, Insight Partners, NVIDIA, Eli Lilly and Company, and others. The funds will advance the company's lead MC4R agonist into Phase I clinical trials by the end of 2026.
Superluminal is transitioning from a discovery platform company to a clinical-stage biotechnology company. This affects internal teams, investors, and potential partners. The existing collaboration with Eli Lilly (worth up to $1.3B) indicates partnership management and data infrastructure needs. The move to clinical trials creates demand for CROs, clinical trial software, and regulatory tools.
The obesity drug market is highly competitive, but Superluminal's focus on rare genetic obesity (Bardet-Biedl syndrome, hypothalamic obesity) addresses unmet needs. The company's AI/ML GPCR platform differentiates it. Potential impacts include:
The Phase I trial start by end of 2026 is a key milestone. Success could validate the platform and lead to additional GPCR-targeted therapies. The Eli Lilly collaboration may expand. Watch for hiring, facility expansion, and procurement of clinical trial software and services.
Source:
BioXconomyGet biotech signals in your CRM
FDA approvals and rejections, clinical trial results, pharma M&A, drug recalls, and funding rounds.
